Note: Descriptions are shown in the official language in which they were submitted.
!~ I
~9L533~
This invention relates to novel che~ical c~mpounds
having anti-viral activity, and more particularly relates to
novel 3, 4-dihydro-3-oxoquinoxal~nes and processes for
preparing same.
Quinoxalines are known which have antiviral
or antibacterial action. For example, Acheson, J.
Chem. SocO 4731 (1950) reports that p-2'-quinoxalinyl-
aminobenzoyl-(-)glutamic acid had a small growth-
inhibitory effect on L. casei. The author also pre-
pared 2-~2-diethylaminoethyl)aminoquinoxaline, the
corresponding 6,7-dichloro derivative and the cor-
responding diethylaminopropyl derivative but found that
all of these compounds were inactive against P. ~al-
linaceum in chicks. 6,7-Dichloro-2-hydroxyquinoxaline-
3-carboxylic acid and its ethyl ester were prepared and
used as intermediates in the production of these
diethylaminoalkylaminoquinoxalines. Belgium patent
769,491 (Derwent abstract 4493T supplied) discloses
2,3-dimercaptomethyl quinoxalines in which the benze~e
ring can be substituted with alkyl, alkoxy, halogen,
tri~luoromethyl, nitro, or alkylenedioxy. The com-
pounds are said to be antiviral agents. 3,6-Diamino-
Z-quinoxaline carboxamides, stated to be useful as
diuretics, anticonvulsants, and antiinflammatory agents, and
to have antiviral activity against ~erpes simplex, are
disclosed in U.S. patent 3,192,212. A group of antiviral
.
~5;33~
X-4398A -2-
quinazolines (isomeric with quinoxalines) are disclosed
in Belgium patent 815,196. A series of antiviral 2-
chloro- or 2-hydrazinoquinoxalines are disclosed in
three papers by Westphal, et al. Pharmazie, 32, 570-571,
687-689, 563-565 (1977). The following types of
compounds were prepared: Quinoxaline-2-ones substituted
in the 3 position with a heterocyclic ring including
benzimidazole, benzothiazole, or benzoxazole (no
utility was given for these compounds); 2 chloro or
2-hydrazinoquinoxalines stated to be active against
coxsackie B, vaccina, sindbas, and pseudorabies viruses;
and, finally, a group of s-triazolo[4,3-a]quinoxalines
prepared by cyclizing a 2-hydrazinoquinoxaline, were
allegedly useful against some of the above viruses.
In addition to the above listed antiviral
agents having the basic quinoxaline structure, there
has been a considerable amount of work carried out on
quinoxaline-1,4-dioxides as antiviral agents. Much of
this work has been summarized in Hurst, et al., Brit.
J. Pharmacol., 8, 297, (1953). According to this
summary, quinoxaline-1,4-dioxides were the most active
compounds tested in experimental psittacosis and
lymphogranuloma venereum infections. A large number of
derivatives of the quinoxaline-1,4-dioxides are sum-
marized on page 301 of the article and include com-
pounds with the following substituents in the quin-
oxaline ring: ethyl, ethoxymethyl, acetoxymethyl,
2-methyl-3-ethyl, 2-methyl-3-carboethoxy, 2,3-dihydroxy-
methyl, 2,3-diiodomethyl, 2,3-bis(dimethylaminomethyl),
etc. Substituents in the benzene ring include: halogens,
. -- .
3~3~
X-4398A -3_
alkyl, nitro, trifluoromethyl, cyano, carboethoxy,
carbamyl, acetamido, etc. (see also Derwent Abstract
5641U abstracting U.K. patent 1,305,138). A similar
group of quinoxaline-1,4-dioxides are disclosed in
Belgian patent 683,206, abstracted as Derwent No.
25,122. Substituted 2-formylquinoxaline-1,4-dioxides
are disclosed in U.S. Patent 3,433,871. The compounds
are said to be antibacterial and antiviral compounds.
U.K. Patent 1,308,370 discloses an improved method of
making substituted quinoxaline-1,4-dioxides having a
variety of substituents in the quinoxaline ring in-
cluding carboxamides (page 13), esters (page 15), a
third ring (page 17-21), acyl derivatives (page 21),
3-hydroxy-2-alkoxy carbonyl derivatives (page 23),
hydroxy carboxamides (page 24), etc. These compounds
are alleged to have in vitro activit~ against harmful
micro-organisms. Antiviral activity is not mentioned.
Another patent relating to methods of preparing quin-
oxaline-1,4-dioxides, is U.K. patent 1,215,815. Page
1 of this patent reviews the literature briefly.
2-Hydroxy-3-carboalkoxyquinoxaline-1,4-dioxides are
named specifically. Finally, U.S. Patent 3,957,387
describes a group of carboxamidoquinoxalinedioxides.
The compounds are alleged to be antibacterial sub-
stances.
Abdulla and Fuhr, J. Heterocyclic Chem.,13 427-432 (1976) prepared ethyl 6,7-dichloro-4,5-
dihydro-3-oxo-2-quinoxaline carboxylate (page 431)
as an intermediate for the production of the previously
unprepared 2-substituted azeto-Ll,2-a]quinoxaline-
1,3-diones, potential antibacterials.
~453~
X-4398A-5 -4-
The above survey of antiviral quinoxalines or
quinoxalines containing various substituent groups and
useful as either antiviral or antibacterial agents is
not exhaustive and merely exemplary of the voluminous
literature on the subject. It should be noted, however,
that there has not been any disclosure of quinoxalin~s
having antiviral activity, particularly against both
Maryland B and Ann Arbor strains of.influenza.virus in
vivc).
This invention in one aspect prov~des a pharmaceutic~l
composition for suppressing viral infection in mammals
infected therewith comprising as active ingredient a
3,4-dihydro-3-oxoquinoxaline of the ~ormula:
R
R2_1~ I ~ nCOOR
R4 H
wh~rein R and R4 are individually ~; Rl and R2 are
individually Cl; R3 is C2H5 and n is 0,and excipients.
~7~ '', ,
X-4398A-5 -5-
This invention also provides a 3,4-dihydro-
3-oxoquinoxaline of the formula:
R
R4 H
wherein R and R are individually H, N02 or CH30; Rl
and R are individually H, N02, CH30 or halo such that
at least one of R, Rl, R2 and R4 is other than H, such
that if neither Rl and R2 is N02 or CH30, both Rl and
R are individually halo and both R and R4 are H, and
such that one of Rl and R2 is CH30 only if one of R,
Rl, R2 and R4 is N02, providing that only one of Rl and
R2 is chloro; R3 is Cl-C4 alkyl, C3-C6 cycloalXyl,
C3-C4 alken~l, H or 2-chloroethyl; and n is 0 or 2.
This invention also provides a process for
the preparati~n of a novel 3,4-dihydro-3-oxoquinoxaline
of Formula I as above described comprising by reacting
the o-phenylene diamine of the formula:
R
~9~
R2~ NH2
R
~1~5337
X-4398A-5 -6-
wherein R,Rl,R2 and R4 are as above described,with an
~-keto dibasic acid of the formula:
o
(CH2) - Co-R3
o~\o_R5
wherein R3 is as above, n is 0 or 2 and R5 is Cl 3
alkyl,at 40 to 110C. in a mutual anhydrous solvent.
This invention also provides a process for the
preparation of a novel 3,4-dihydro-3-oxoquinoxaline of
Formula I as above described wherein both R and R4 are
hydrogen comprising reacting a 2-nitro 4,5-disub-
stituted aniline of the formula:
~-b
RZ-&~ NHz
lV
wherein Rl and R2 are as above~with an alkyl malonyl
chloride of the fo~nula:
o¢=o-R3
CH2
O=C Cl
wherein R3 is as above,in an inert mutual solvent at
50 to 115C. to yield the corresponding alkyl malonyl
~mide on the aniline nitrogen;
followed by annelation in the presence of sodium
ethoxide at 0C t~ yield the quinoxaline Nl-oxide;
followed by treatment with phosphorus trichloride in
an inert solvent at 5 to 25C.
3~
X-4398A -7~
Compounds coming within the scope of the
above formula are prepared by reacting a suitably
substituted o-phenylenediamine with a dialXyl 2-
ketomalonate (a dialkyl mesoxalate) when n is 0 or
a dialkyl 2-ketoglutarate when n is 2. The reaction
is carried out in a mutual anhydrous solvent at 40
to 110C, customarily at reflux temperature of the
solvent and is illustrated below in the following
reaction scheme:
REACTION SCHEME I
O
15R ~ )1 NHz ~ O ~(CH )n COalhyl
R4 0~ Oa l ky l
R R4
h -~ O R2-~ I CH~) COOalhyl
2 5 F`<4 I R H
II III
7r~ .
1~,~
33~
X-4398A -8-
According to Reaction Scheme I, if R and R
are hydrogen and Rl and R2 are the same substituent;
i.e., Cl, or Br, for example, only one product (repre-
sented by either II or III) will result, but if the
starting o-phenylenediamine is unsymmetrically sub-
stituted, i.e., R or R4 is other than hydrogen or Rl
and R2 are not identical, a mixture of isomeric products
will result as represented by formulas II and III. The
various ester groups which R3 represents can be incor-
porated in the 3,4-dihydro-3-oxoquinoxalines in one of
two ways. First, the initial reactant, the mesoxalate,
can be esterified with Cl-C4 alkyl groups (corresponding
to Formula I wherein R is Cl-C4 alkyl) or other groups
represented by R . Thus, in the final product, whether
it be formula II or III, the ester group would be the
same as that present in the starting material. Secondly,
the alkyl ester of Formula II or III can be hydrolyzed
to yield the free acid (those compounds of Formula I in
which R3 is H) and this free acid can in turn be re-
esterified with a C3-C6 cycloalkyl group, a C3-C4
alkenyl group or a Cl-C4 alkyl group.
In the above reaction scheme, when R and R2
are different groups, the product of the reaction of
the substituted o-phenylenediamine and diethyl mesoxalate
is a mixture of compounds represented by formulas II
and III above. A reaction procedure for the unequivocal
synthesis of a given compound coming within the scope
of this invention in which n is 0 is illustrated in
Reaction Scheme 2 below:
X-4398A -9-
Reaction Scheme 2
~ O EtO-CO-CH2-CO-CI \ R t ~ NO2
R2- ~ ,-NH2 =loluene, Heat / 22_ ~ ~-NH
V CO-CH2-CO-OE,
IV
EtONa
\~ / EtOH
R1~ -COOEt / PC13 R~ COOEt
R2- ~ /-\ / =o \ THF R2_ ~ /o\ ~ O
H H
VII VI
in which Rl and R2 have their previously assigned
meaning.
According to ~eaction Scheme 2, a 2-nitro-
4,5-disubstituted aniline (IV) is reacted at 50 to
115C. in an inert mutual solvent with ethyl malonyl
chloride (or other alkyl malonyl halide) to give the
corresponding ethyl malonyl amide derivative on the
aniline nitrogen (V). A base catalyzed annelation
using sodium ethoxide at 0C. yields the quinoxaline
-oxide (VI) r treatment of which with phosphorus
trichloride in an inert solvent, for example, tetra-
hydrofuran (THF) at 0 to 25C. temperature produces
unambiguously a 6,7-disubstituted-3,4-dihydro-3-
oxo-2-quinoxaline carboxylate, ethyl ester (VII).
X-4398A -10-
Compounds preparable by the above procedures
include the following:
n-propyl 6-iodo-7-chloro-2,3-dihydro-
3-oxo-2-quinoxaline carboxylate,
n-propyl 6-chloro-7-iodo-2,3-dihydro-
3-oxo-2-quinoxaline carboxylate,
methyl 6,7-dichloro-2,3-dihydro-3-oxo-2-
quinoxaline propionate,
8-nitro-2,3-dihydro-3-oxo-2-quinoxaline
carboxylic acid,
6-fluoro 7-bromo-2,3-dihydro-3-oxo-2
quinoxaline carboxylic acid,
allyl 6-fluoro-7-nitro-2,3-dihydro-3-
oxo-2-quinoxaline propionate,
methyl 7-methoxy-8-nitro-2,3-dihydro-
3-oxo-2-quinoxaline carboxylate,
n-butyl 6-iodo-7-nitro-2,3-dihydro-3-
oxo-2-quinoxaline carboxylate,
isobutyl 7-nitro-8-chloro-2,3-dihydro-3-
oxo-2-quinoxaline carboxylate,
methallyl 6,7-difluoro-2,3-dihydro-3-
oxo-2-quinoxaline propionate.
The abova compounds are particularly useful
in treating or preventing viral infections caused
by influenza vixus in vivo. Infection caused by
Maryland B and Ann Arbor strains, representative of
the A and B strains of the virus, of influenza
viruses are treatable by compounds according to
formula I. A particular subgroup of very active
agents against influenza infections in vivo are
compounds of the following structure:
X-4398A
R -~8\1/ ~ -COOR
R2- ~ /o ~I=o
X H
in which Rl and R2 are halogen or one of R2 and Rl is
nitro and the other is H and R3 is Cl-C4 alkyl,
preferably methyl or ethyl. Particularly active
antiviral agents represented by Formula X include:
ethyl 6,7-difluoro-3,4-dihydro-3-oxo-2-
quinoxaline carboxylate
ethyl 6,7-dichloro-3,4-dihydro-3-oxo-2-
quinoxaline carboxylate
ethyl 6,7-dibromo-3,4-dihydro-3-oxo-2-
quinoxaline carboxylate
ethyl 6,7-diiodo-3,4-dihydro-3-oxo-2-
quinoxallne carboxylate
ethyl 6-chloro-7-bromo-3,4-dihydro-3-
oxo-2-quinoxaline carboxylate
ethyl 6-bromo-7-chloro-3,4-dihydro-3-
oxo-2 quinoxaline carboxylate
ethyl 7-nitro-3,4-dihydro-3-oxo-2-quinoxaline
carboxylate
The preparation of the above compounds is
illustrated by the following specific examples:
X-4398A -12-
Example 1
Preparation of Ethyl 6,7-Dichloro-3,4-dihydro-3-
oxo-2-quinoxaline Carboxylate.
A solution of 17.7 g. of 4,5-dichloro-o-
phenylenediamine and 200 ml. of anhydrous ethanol was
prepared. A 17.4 g. batch of diethyl 2-keto-malonate
was added to this solution and the mixture was heated
to refluxing temperature for about 17 hours. The
volatile constituents were removed by evaporation in
vacuo. Recrystallization of the residue from ethanol
yielded 20 g. of ethyl 6,7-dichloro-3,4-dihydro-3-
oxo-2-~uinoxaline carboxylate formed in the above
reaction; melting in the range 226-227C.
Exam
Preparation of Ethyl 6-Chloro-7-bromo-3,4-dihydro-3-
oxo-2-quinoxaline Carboxylate.
Five grams of 2-nitro-4-bromo-5-chloro-
anili~e were dissolved in 150 ml. of benzene. Five
grams of the acid chloride of monoethyl malonate were
added with stirring under a nitrogen atmosphere. The
reaction mixture was heated to refluxing temperature
overnight. Thin-layer chromatography indicated that
the reaction was essentially complete at this time.
The reaction mixture was cooled and the benzene
removed by evaporation in vacuo. The residue con-
taining ~-ethoxycarbonylacetyl 2-nitro-4-bromo-5-
chloro)aniline formed in the above reaction, was re-
crystallized from anhydrous ethanol to yield fluffyyellow crystals melting at 119-121C.
X-4398A -13-
Sodium ethoxide was prepared under anhydrous
conditions from 35 ml. of anhydrous ethanol ~nd 1 g.
of sodium in a nitrogen atmosphere. The mixture was
stirred until the sodium was dissolved completely
after which time the mixture was chilled to about 0C.
N-ethoxycarbonylacetyl 2-nitro-4-bromo-5-chloroaniline
was added and the resulting mixture was stirred at
0C. for about 3 hours. The reaction was then
quenched by adding it to 300 ml. of lN aqueous hydro-
chloric acid at OGC. This aqueous mixture was stirreduntil a solid precipitate formed. The precipitate was
separated by filtration, dried, and the filter cake
was recrystallized from anhydrous ethanol. Ethyl 6-
chloro-7-bromo-3-oxo-2-quinoxaline carboxylate N-
oxide thus prepared melted at 219-221C.; yield = 2 g.
Analysis Calc.: C, 38.01; H, 2.32; N, 8.06
Found: C, 37.79; H, 2.35; N, 8.24
~ ne gram of ethyl 6-chloro-7-bromo-3-
oxo-2-quinoxaline carboxylate N-oxide was dissolved in
50 ml. of THF. SiX ml. of phosphorus trichloride were
added and the resulting mixture heated gently at
refluxing temperature overnight. The reaction mixture
was poured into 500 ml. cf an ice~water mixture. A
solid, comprising ethyl 6-chloro-7-bromo-3,4-dihydro-
3-oxo-2-quinoxaline carboxylate formed in the above
reaction, was separated by filtration; melting point =
203-205~C; yield - 0.6 g.
X-4398A -14-
Example 3
Preparation of Ethyl 6,7-Difluoro-3,4-dihydro-3-
oxo-2-quinoxaline Carboxylate.
About 25 ml. of acetic anhydride were added
cautiously to 25.8 g. of 3,4-difluoroaniline. The
mixture was stirred for 1 hour after the addition was
complete and was then poured over ice. The resulting
white precipitate comprising 3,4-difluoroacetanilide
was separated by filtration, and dried. ~ecrystal-
lization from a benzene-acetone solvent mixture yielded
30 g. of 3,4-difluoroacetanilide melting at 125-6C.
Analysis Calc.: C, 56.14; H, 4.12; N, 8.12
Found: C, 56.28; H, 4.22; ~J, 8.16
A solution of 8.5 g. of 3,4-difluoroacetanilide
was prepared in 50 ml. of 18 M sulfuric acid, and was
chilled to about 0C. A 10.5 g. portion of propyl
nitrate was added in dropwise fashion. The consequent
reaction mixture was stirred at about 0C. for two
hours and was then poured over an ice-water mixture.
A pale yellow precipitate comprising 4,5-difluoro-
2-nitroacetanilide formed in the above reaction was
separated by filtrationO The filter cake was washed
several times with water and then recrystallized from
an ethanol-water solvent mixture (yield = 9 g.). The
compound melted at 105-107C.
Analysis Calc.: C, 44.46; H, 2.80; N, 12.96
Found: C, 44.24; H, 2.76; N, 12.88
,,~.
3'~ 3'7
X-4398A -15-
A mixture of 6.51 g. of 4,5-difluoro-2-nitro-
acetanilide and 100 ml. of 6N aqueous hydrochloric acid
was heated to refluxing temperature for about 2 hours.
The reaction mixture was then cooled. Crystals which
formed were separated by filtration, and the separated
crystals were ~ashed with water, dried, and recrystallized
from a hexane-dichloromethane solvent mixture. A yield
of 5.0 g. of 4,5-difluoro-2-ni-troaniline was obtained,
melting at 106-108C.
Analysis Calc.: C, 41.39; H, 7.32; N, 16.07
~ound: C, 41.41; H, 7.35; N, 15.85
A reaction mixture was prepared containing
8.75 g. of 4,5-difluoro-2-nitroaniline, 200 ml. of
ethanol, and as a catalyst 1 g. of 10 percent palladium-
on-carbon. The mixture was hydrogenated until the
theoretical amount of hydrogen had been absorbed, using
a low-pressure hydrogenation apparatus. The catalyst
was separated by filtration using standard precautions
and the product of the reaction, 4,5-difluoro-o-phenyl-
enediamine, was reacted with diethyl mesoxalate follow-
ing the procedure of Example 1 without further purifica-
tion. The product of this reaction, ethyl 6,7-difluoro-
3,4-dihydro-3-keto-2-quinoxaline carboxylate, melted at
about 193-195C.
Example 4
Preparation of 6,7-Difluoro-3,4-dihydro-3-oxo-2-
quinoxaline Carboxylic Acid.
To 2.42 g. of ethyl 6,7-difluoro-3,4-
dihydro-3-oxo-2-quinoxaline carboxylate were added
X-4398A -1~-
~0 ml. of 2N aqueous sodium hydroxiZe. The mixture was
heated to refluxing temperatures for 3 hours and was
then treated with charcoal, cooled, and filtered. The
filtrate containing 6,7-difluoro-3,4 dihydro-3-
oxo-2-quinoxaline carboxylic acid formed in the above
reaction was acidified with 12N aqueous hydrochloric
acid. The acid, being insoluble in the aqueous acidic
mixture, precipitated and the precipitate was separated
by filtration. The filter cake was crystallized from
an ethanol-acetone solvent mixture to yield 1.3 g. of
6,7-difluoro-3,4-dihydro-3-oxo-2-quinoxaline carboxylic
acid melting at 220-225C.
Analysis Calc.: C, 47.80; H, 1.78; N, 12.39
Found: C, 47.73; H, 1.94; N, 12.63
Example 5
Preparation of Ethyl 6,7-Diiodo-3,4-dihydro-3-oxo-2-
quinoxaline Carboxylate
A reaction mixture was prepared containing
76 g. of 20% oleum, 10 g. of iodine and 10 g. of o-
dinitrobenzene. The reaction mixture was stirred at a
temperature in the range 170-175C. for 2 hours and was
then cooled. The cooled reaction mixture was poured
onto ice and then filtered. The filter cake, compris-
ing 1,2-dinitro-4,5-diiodobenzene formed in the above
reaction, was dissolved in 1 1. of ether. The ether
solution was washed with aqueous bisulfite and saturated
aqueous sodium bicarbonate, and then dried. The ether
was removed therefrom in vacuo, and the crude solid
residue crystallized from ethanol to yield brownish
plates consisting of 1,2-dinitro-4,5-diiodobenzene
melting at 177-178C.
X-4398~ -17-
A solution was prepared from 3 gms. of 1,2-
dinitro-4,5-diiodobenzene in 150 ml. of ethanol.
Gaseous ammonia was passed into the solution while
heating to refluxing temperature. This procedure was
continued until TLC indicated that all starting mate-
rial had reacted (about 8 hours). The volume of the
solution was then reduced to l/3 of the original
volume and the solution was cooled. 2-nitro-4,5-
diiodoaniline formed in the above reaction precipitated
and was collected by filtration; mp = 196-7C.
yield = 1.70 g.
Analysis Calc.: C, 18.48; H, 1.03; N, 7.18
Found: C, 18.65; H, 1.08; N, 7.33
A reaction mixture was prepared from 1.2 g.
of 2-nitro-4,5-diiodoaniline, 1.8 g. of stannous
chloride and lO ml. of 12N aqueous hydrochloric acid.
The reaction mixture was heated to a temperature in the
range 80-100C. with stirring. The original deep
yellow color of the solution was soon discharged.
After 2 hours of heating and stirring, the reaction
mixture was dumped into a mixture of 100 ml. of water
and 25 ml. of aqueous sodium hydroxide. ~ tan solid
consisting of 4,5-diiodo-o-phenylenediamine precipi-
tated and was collected by filtration; yield = 0.9 g.
~ solution was prepared from 0.9 g. of 4,5-
diiodo-o-phenylenediamine and 25 ml. of ethanol. Five
grams of diethyl ketomalonate were added and the
resulting mixture was heated to refluxing temperature
3'7
X-4398A -18-
with stirring overnight. The reaction mixture was
then cooled. Ethyl 6,7-diiodo-3,4-dihydro-3-oxo-
2-quinoxaline carboxylate formed in the above reaction
precipitated and was collected by filtration; yield =
0.8 g.; mp = 275-276C.
Analysis Calc.: C, 28.09; H, 1.70; N, 5.96
Found: C, 28.01; H, 1.72; N, 6.07
Example 6 -
Hydrolysis of Ethyl 6,7-Dichloro-3,4-dihydro-2-
oxo-3-quinoxaline Carboxylate.
One gram of ethyl 6,7-dichloro-3,4-dihydro-
2-oxo-3-quinoxaline carbo~ylate was dissolved in a
mixture of 25 ml. of isopropanol and 75 ml. of water.
Five grams of potassium hydroxide were added and the
resulting mixture heated to reflux temperature for 5
minutes. The hot reaction mixture was decolorized
with activated charcoal and filtered. The filtrate
was acidified with 12N aqueous hydrochloric acid.
Needle-like yellow crystals precipitated comprising
6,7-dichloro-3,4-dihydro-2-oxo-3-quinoxaline car-
boxylic acid formed in the above hydrolysis. The acid
was collected by filtration; mp = >300C.
Example 7
Preparation of esters.
6,7-Dichloro-3,4-dihydro-3-oxo-2-quinoxaline
carboxylic acid prepared from the corresponding ethyl
ester by the procedure of Example 6 was es~erified with
methanol according to the following procedure:
X-4398A -19-
Two grams of the free acid and 20 ml. of anhydrous
methanol were mixed with a catalytic quantity of boron
trifluoride etherate dissolved in methanol. The
mixture was heated to refluxing temperature for 60
hours after which time it was cooled and filtered.
Methyl 6,7-dichloro-3,4-dihydro-3-oxo-2-quinoxaline
carboxylate separated and was isolated by filtration;
weight = 153 g.; color = greenish yellow; mp - 258-260C.
Exam~le 8
Alternate ester preparation
One gram 6,7-dichloro-3,4-dihydro-3-oxo-2-
quinoxaline carboxylic acid prepared by the hydrolysis
of the ethyl ester by the procedure of Example 6 was
suspended in 100 ml. of benzene. To this suspension
was added 10 ml. of thionyl chloride. The resulting
mixture was heated to refluxing temperature for two
hours after which time the volatile constituents were
removed by evaporation in vacuo. The residue, com-
20 prising 6,7-dichloro-3,4-dihydro-3-oxo-2-quinoxaline
carboxyl chloride, was mixed with 50 ml. of isopropanol
and the resulting mixture heated to refluxing tem-
perature for 48 hours. Excess isopropanol was removed
by evaporation in vacuo to yield 1.05 g. of isopropyl
25 6,7-dichloro-3,4-dihydro-3-oxo-2-quinoxaline carboxylate
as a pale yellow solid which melted at 210-211C. after
recrystallization from isopropanol.
Analysis Calc.: C, 47.86; H, 3.35; N, 9.30
Found: C, 48.16; H, 3.44; N, 9.28
X-4398 -20-
The corresponding allyl ester was prepared b-~
the above procedure; melting point = 228-230C. wi~h
decomposition.
Analysis Calc.: C, 48.19; H, 2.70; N, 9.37
Found: C, 47.89; H, 2.66; N, 9.42
The corresponding n-butyl ester was prepared
by the above procedure, and melted at 177-178C. after
recrystallization from isopropanol.
Analysis Calc.: C, 49.54; H, 3.84; N, 8.89
Found: C, 50.56; H, 3,80; N, 8.94
Example 9
Preparation of Ethyl 6,7-dibromo-3,4-dihydro-3-
oxoquinoxaline Carboxylate.
Ten g. of 3,4-dibromoaniline were mixed with
40 ml. of acetic anhydride. The resulting reaction
mixture was heated to a temperature in the range
100-105C. for one hour after which time it was poured
over a mixture of ice and watér. After stirring
overnight, the aqueous mixture yielded an off-white
precipitate weighing 11.5 g. and melting at 90~95C.
comprising 3,4-dibromoacetanilide.
2.5 g. of 3,4-dibromoac~tanilide were mixed
with 8 ml. of 18N aqueous sulfuric acid at 0C.
1.5 g. of propyl nitrate were added while maintaining
the reaction temperature in the range 0-2C. The
chilled reaction mixture was stirred for one hour in
the same temperature range and then poured over an ice-
water mixture. A yellow solid comprising 4,5-
-,
X-4398A -21-
dibromo-2-ni-troacetanilide formed in the above reaction
precipitated and was collected by filtration. Recrys-
tallization from ethanol yields 1.2 g. of 3,4-dibromo-
6-nitroacetanilide melting at 140-141C.
One gram of 4,5-dibromo-2-nitroacetanilide
was heated to refluxing temperature for 30 minutes with
30 ml. of 6N aqueous hydrochloric acid. The reaction
mixture was then poured over an i,ce-water mixture and
stirred. The pH of the solution was adjus~ed ~o 12
with alkali. The resulting bright yellow precipitate
was separated by filtration, washed and dried; yield =
0.85 g of 4,5-dibromo-2-nitroaniline melting at 204-205C.
Five grams of 4,5-dibromo-2-nitroaniline were
suspended in 200 ml. of anhydrous ethanol to which was
added about 10 g. of Raney Nickel. The hydrogenation
mixture was placed in a low pressure hydrogenation
apparatus at a hydrogen pressure of 55 psi. A rapid
uptake of hydrogen occurred which ceased after about 25
minutes, at which time the deep yellow color originally
present was discharged indicating complete reduction of
the nitro group to an amine group. The hydrogenation
was continued for another half hour and the hydrogen-
ation mixture was then worked up by filtering off the
catalyst, washing the filtered catalyst, and stripping
the volatile constituents from the filtrate. A yield
of 4.1 g~ of 4,5-dibromo-o-phenylenediamine was obtained.
b ~ 5 ~
X-4398A -22-
4,5-Dibromo-o-phenylenediamine was cyclized
to the corresponding quinoxaline carboxylic acid ester
by the procedure of Example l utilizing 4.1 g. of the
diamine and 2.7 g. of diethyl ketomalonate in 75 ml. of
anhydrous ethanol. Ethyl 6,7-dibromo-3,4-dihydro-3-
oxo-2-quinoxaline carboxylate thus prepared melted at
235-236C. (yield = 3.9 g.).
Example 10
Preparation of Ethyl 3-(6,7-dibromo-3,4-dihydro-3-
oxo-2-quinoxaline)propionate
Following the procedure of Example 9, 5 g. of
3,4-dibromo-6-nitroaniline were reduced in anhydrous
ethanol with Raney nickel to yield 4,5-dibromo-o-
phenylenediamine which was not isolated but mixed
immediately with 2.47 g. of 2-ketoglutaric acid. One
hundred ml. of ethanol were added and the mixture
heated to refluxing temperature for 3 hours. 3 gms. of
~-(6,7-dibromo-3,4-dihydro-3-oxo-2-quinoxaline)p o-
pionic acid were obtained melting at 249-250C. The
free acid was converted to the corresponding ethyl
ester by the procedure of Example 8. Ethyl ~-(6,7-
dibromo-3,4-dihydro-3-oxo-2-quinoxaline)propionate thus
prepared melted at 189-190C.
Following the above procedure, 4,5-dichloro-
o-phenylenediamine was reacted with 2-ketoglutaric acid
in ethanol to yield 6,7-dichloro-3,4-dihydro-3-oxo-
2-quinoxaline propionic acid. Reaction of the
33~
X-4398A -23-
free acid ~ith ethanol in the presence of BF3 etherate
yielded the corresponding ethyl ester, ~-(6,7-dichloro-
3,4-dihydro-3-oxo-2-quinoxaline)propionic acid, ethyl
ester melting at 183.5-184.5. The free acid had the
following analysis.
Analysis Calc.: C, 46.02; H, 2.81; N, 9.76
Found: C, 45.79; H, 2.53; N, 9.64
Examplè 11
Preparation of Ethyl 6(7)-Chloro-7(6)-~romo-3,4-
dihydro-3-oxo-2-quinoxaline Carboxylate.
3-Chloro-4-bromoacetanilide prepared by the
procedure of Example 9 was nitrated in 18 M aqueous
sulfuric acid with propyl nitrate at 0C. according to
the procedure of Example 9, The product of reaction
was worked up by adding it to a mixture o, ice and
water with stirring. A yellow powder comprising 4-
bromo-5-chloro-2-nitroacetanilide precipitated and was
collected by filtration. Recrystallization from
ethanol gave crystals melting at 128-130C.; yield =
38 g.
4-Bromo-5-chloro-2-nitroacetanilide was
hydrolyzed to the free amine by the process of E~ample
3. Reduction of 5 g. of 4-bromo-5-chloro-2-nitro-
aniline thus formed with P~aney nickel by the procedure
of Example 9 yielded 3.35 g. of 4-bromo-5-chloro-o-
phenylenediamine. A 1.66 g. portion of the diamine
were reacted with 0.85 g. of diethyl ketomalonate by
refluxing in a mutual solvent for 2.5
X-4398A -24-
hours. ~ellow, needle-like crystals comprising ethyl
6(7)-chloro-7(6)-bromo-3,4-dihydro-3-oxo-2-quinoxaline
carboxylate precipitated and were collected by filtra-
tion; mp = 185-195C.; yield = 111 g.
Following the above procedure, 4-nitro-
o-phenylenediamine was reacted with diethyl ketomal-
onate to yield ethyl 6(7)-nitro-3,4-dihydro-3-oxo-2-
quinoxaline carboxylate. The compound solidified after
cooling. The solid was isolated by filtration and theO filter-cake washed with isopropanol. Yield = 70 pecent.
Analysis Calc.: C, 50.20; H, 3.45; N, 15.96
Found: C, 50.36; H, 3.50; N, 16.10
Example 12
Preparation of ~-Chloro-Ethyl 6,7-Dichloro-3,4-
dihydro-3-oxo-2-quinoxaline Carboxylate
6,7-Dichloro-3,4-dihydro-3-oxo-2-quinoxaline
carboxyl chloride was prepared according to the pro-
cedure of Example 8. The acid chloride (2.2 g.) was
stirred with an excess of ~-chloroethanol at 130C. for
2 hours under a nitrogen atmosphere. Excess ~-chioro-
ethanol was removed by evaporation in vacuo at 50C.
The residue compound, ~-chloro-ethyl 6,7-Dichloro-3,4-
dihydro-3-oxo-2-quinoxaline carboxylate was recrystal-
lized from iso-propanol-acetone solvent mixture to
yield 1.55 g. fluffy yellow flakes melting at 214-215C.
33~
X-43~8A -25-
Example 13
Pre~aration of Cyclobutane methyl 6,7-Dichloro-3,4-
dihydro-3-oxo-2-quinoxaline CarbQxylate
Five grams of 6,7-dicnior~-3,4-dihYdro-3
oxo-2-quinoxaline carboxylic acid prepared by the
procedure of Example 6 were mixed with 25 g. of cyclobutyl
methanol and 5 ml. boron trifluoride etherate in a 50 ml.
round bottom flask. The reac~ion mixture was refluxed
at 140C. for 2 hours with all starting mat~rial
having dissolved. Thin layer chromatography showed
that no starting material remained. On cooling
lustrous yellowish-tan needles crystallized out. The
reaction mixture was diluted with 25 ml. iso~propanol
1~ and refrigerated. The product, cyclobutane methyl
6,7dichloro-3,4-dihydro-3-oxo-2-quinoxaline car~oxylate,
w~s separated out by filtratioh and washed once with
25 ml. hexane to yield 3.55 g. with the melting point,
183-184C.
Example 14
. .
Preparation of Ethyl 6-Nitro-8-chloro-3,4-dihydro-3-
oxo-2-quinoxaline carboxylate and Ethyl 7-Nitro-5-
chloro-3,4-dihydro-3-oxo-2-quinoxaline Carboxylat~
3-Chloro-5-nitro-o-phenylenediamine (1.87 g.)
was dissolved ir. 15 mlq of anhydrous ethanol~
and 1.8 g. diethyl ketonalonate was added~ The
solution was heated to refluxing temperature for 24
hours. The volatile constituents were removed by
evaporation in vacuo. Recrystallization of the residue
~0 from an ethanol solution yielded the mixture of ethyl
6-nitro-8-chloro-3,4-dihydro-3-oxo-2-quinoxaline car-
boxylate and its isomer ethyl 7-nitro-5-chloro-3,4-
~j
5337
X-4398A -26-
dihydro-3-oxo-2-quinoxaline carboxyla$e having a
melting point 180-200C.
Example 15
Preparation of Ethyl 6-Methoxy-B-nitro-3, 4-dihydro-3-
oxo-2-quinoxaline Carboxylate and Ethyl 7-Methoxy-
~nitro-3,4-dihydro-3-oxo-2-quinoxaline Carboxylate
3 Nitro-5-methoxy-o-phenylenediamine (1.83 g.)
was dissolved in 25 ml. of anhydrous ethanol and 1.8 g~
of diethyl ketomalonate was added. The mixture was
refluxed for 48 hours. The volatile constituents were
evaporated in vacuo. The residue was recrys~allized
from a propanol-ethanol solution yielding 2.2 g. of the
mixture of ethyl 6-methoxy-8-nitro-3,4-dihydro-3-
oxo-2-quinoxaline carboxylate and its isomer ethyl
7-methoxy-5-nitro-3,4-dihydro-3-oxo-2-quinoxaline
carboxylate.
Table 1 below lists compounds prepared by one
of the above reaction procedures. The table gives the
particular substituent groups, indicates whether the
compound was prepared in pure form or as a mixture of
isomers, and gives the elemental analysis (calculated
and found) for each compound. In addition, a letter
had been assigned to each compound in order to facilitate
the reading of the test results in subsequent tables.
i: ~ f
i,, ~
X-4398A -27-
o ~r o L~ o
~1 ~ ~ C~ 00 o s;~
a Z ~D ~ O ~ O ~ ~0
~ '' ~ ~,
O o ~ L~
U~ X u~
Z ~ ~` ~ ~ ~ o U~
C~ o ~ ~P ~ ~ a: o
Lr~ ~ e
~ ~ ~ ~ ~ U~ ~
Z ~ r~ N i` ~0 ~ CO -
~) ~ o a~ o 1.) co
1 ~
o ~ I L~ ~ o ~r
v~ ~ 1 ~ ~ ~ ~ ~ .
c H t`~
C~l ~
f~ 1 o a~ o r- o ~n
~1 i~ ~ -- I O U~
~1 ~--
~ / \
O O ~ O O O O O
m
::C O ,~ ~ ~1
Z ~ U C~
Z ~ ) H
~1
~;
~1
m c~
33~
X- 4 39 8A -2 8 -
~ J ~7 ~D CO Y) O ~
CO t~ S) 1~ 0 0
3 z
Z o a~
O
æ ~ ~ O a~ 1-
~¢ ~ ~ ) ~ l G CO (~ ~ ~r ~ 1
o~ o i-- ~ u~ co o~ u~ ~ 00 ~r
O ~ !` ~ Ln
Z
C ) r~
g
r-- u~ ~ o o ~r 1-- ~ ~ ~ 00
H X
r~ ~
~¢
Z
O ~: ~ U) ~ O er ~ ~ ~ ~ I
a) o ~ ~r ~ ~g U~ ~ co ,~
a)
~ OOOOO O~OOOOoO
E~
,~
O
.~I ~ O ~ S ,r~ C S
o ~ U ;~ ~ ~ ~ ~ ~3
U~ I
O
O
~; ~ c~ u c~ c) m m c~ m o m ~:: x z
t,
m ~ oz ~;
~ ~ ~ ~c ~
$ ~ ~ $
~ z z o ~
~ u~
O U~
O ,.. , H 1'7 ;Y; 1~ ~ Z 0 ~4 Cl P:~
C~
S~37
X-4398A -29-
The compounds represented by Formulas I, II,
III or X above are active both in vitro and in vivo
against two different strains of influenza virus,
Maryland B and Ann Arbor. In vitro antiviral activity
S was determined as follows:
African green monkey kidney cells (BSC-l) or
Hela cells (5-3) were grown in 25 cc."Falcon flasks at
37C. in medium 199 with 5 percent inactivated fetal
bovine serum (FBS), penicillin (150 units 1 ml.) and
streptomycin ~150 mcg./ml.). When confluent monolayers
were formed, the supernatant growth medium was removed
and 0.3 ml. of an appropriate dilution of Maryland B or
Ann Arbor influenza virus was added to each flask.
After adsorption for one hour at room temperature, the
virus infected cell sheet was overlaid with a medium
comprising one part 1 percent"Ionagar"No. 2 and one
part double strength medium 199 with FCS (fetal calf
serum), penicillin, and streptomycin and also contain-
ing drug at concentrations of 100, 50, 25, 12, 6 and 3
micrograms per milliliter (mcg./ml.). The flask con-
taining no drug served as a control. The stock solutions
of the quinoxalinone compounds were made up in dimethyl-
sulfoxide dilution at a concentration of 104 mcg./ml.
The flasks were incubated for 72 hours at 37C. Plaques
were seen in those areas where the virus infected and
,reproduced in the cells. A solution of 10 percent formalin
and 2 percent sodium acetate was added to each flask to
inactivate the virus and fix the cell sheet to the
surface of the flaskO The virus plaques, irrespective
* Trademark
** Trademark
~.~.
X-4398A -30-
of size, were counted after staining the surrounding
cell areas with crystal violet. The plaque count was
compared to the control count at each drug concen-
tration. The activity of the compound was expressed
as percentage plaque inhibition. In Table 2 which
follows, column 1 gives the letter assigned to the
compound, and columns 2 and 4 the I50, amount of drug
in mcg/ml which inhibits 50~ of the plaques.
In vivo activity was determined as follows:
White Swiss female mice (11-13 g.) McAllister strain
were infected with aqueous dilutions of Ann Arbor or
Maryland B strains of influenza virus in an air borne
injection apparatus. Graded dose levels of the drug were
injected intraperitoneally (IP) or administered orally
(OR) by gavage 24 and 4 hours preinfection and 24
and 48 hours postinfectionc Date of death was deter-
mined. The drug was administered in water containing
2~ of a surfactant. In Table 1, column 7, a dosage
level for each drug is given at which there was a
statistically significant increase in survival and
column 6 gives the route of administration.
37
X- 4 3 9 8A - 3 1 -
C: o o o o o
co Ln
o ~
~ o
,i
5~ r1 r~ ~
o ~ a) o
,¢ N O ~ ~ ~ O
0:; H H H H H CO
s ,~
O O .1 ~D L~
H ~ L~ O
i~
V
.,
U~
m
~ r~
1 N
h O
O
o
~ ~1 o ,~
H ~ U ) O O CO r~ CO V Cl~
H ~r ~ ~ I~
V V
Q ~ m c~ H r~ ~;
r~o
3~
X-439 8A -32--
~ o
C CO
a) o o o o
O u~ ~r c~ co co
~ O
,
5~ ~
0~ ~ O
~ t~J 5 ~.
,~ N ~0 1~ 1 H H
a)
O
S~
O
') O
H tN
~i
O ~ 5~
r~l N
O
~ ~1 0
H ~ 111 U~
H
03 ~ ~: 01 ~ u~
C,)
37
X-4398A -33-
The compounds represented by Formulas I,
II, III or X have also shown activity in vitro
against other viruses in a plaque suppression test
similar to that used in determining activity against
Maryland B or Ann Arbor influenza virus. Table 3
which follows summarizes the results of these tests.
In the table, column l gives the alphabetic symbol for
the compound, column 2 the virus against which the
compound was tested and column 3, the dose level in
micrograms per ml. at which activity was found.
3~
X-4398~ -34- -
,~ o o
o o
o o
O tJ) N N
l l
0 00 0000 0 00 000 0 000
~ t5~O O O O O O O O O O O O O O O O O
V C) O O O O O O O O O O O O O O O O O
~ N N N N ~1 ~ ~1 ~ N ':`;J N N N t''l N N N
a~
'~ ~ X X
F~ N 0 a) u~ o o
0 I ~ ~ a) ~ ~
~1 ~ rl H ~ r/ rt
rJ H (~ 0 ~ 0 ~ 0 07
~r~ 0,~ rl O ~ 1 0 ~1
~ r-l V ,Y ~ 0 ~ 0 S ~ 0
rl ~ rl O-r~ 1 o rl-rl
V 0 0 ~I-r~ O O-rl _~ V ~ V O
t) ~: X E~ ~ V S~
~ o o a~ o ta tu o (1~ O
O O
O ~'
tl~
3~
X-4398A -35-
o o o o o o o o o o o o o o
o oo o o o ooo oo ooo
o o o o o o o o o o o o o o
.~
o
-
~ X X X X
U~ ~ ~ ,1 ~
s~ ~ E E E
t~ ~ U~ H ~
E~ O O O O~ H rl O O-rl
1 o-~
O O rI t) ~ O O
o t~ ~J a) o t) ~ o
~ ~1
i3 E :~: ~ o ~ ol P~
, . . .
.. ' ~' ,
5;~3~
X-4398A -36-
Quinoxaline-2-carboxylates~ according to
formulas I, II, III or X above, have been shown by the
above tables to have both in vivo and in vitro activity
against influenza virus, both A and B strains, and to
have in vitro activity against other viruses. For in
vitro use, the compounds can be formulated by dis-
solving them in a lower alkanol, for example ethanol
or methanol, or at low concentration as an emulsion in
water with the use of a surface active agent~ If R
in formula I is H, an alkali metal salt of the acid
can be used in aqueous solution. The antiviral
composition containing a quinoxaline according to
formula I as the active ingredient is, therefore,
applied to the virus habitat in vitro, such habitats
including walls of hospital rooms, laboratory benches,
laboratory glassware, and the like. The compounds can
also be added to tissue culture to suppress viral
growth therein. For in vivo use, the compounds can be
administered either parenterally or orally. For
parenteral administration, as by the intraperitoneal
route employed in the above experimental work, the
compound may be dissolved in water containing 2% of a
surface active agent, particularly an"Emulphor"~a
polyhydroxylated fatty acid). Oral administration i9,
of course, preferred. For such use, a quinoxaline
according to formula I above is mixed with one or more
standard pharmaceutically-acceptable extending media
su~h as starch, sucrose, lactose, calcium carbonate
etc. and the mix~ure loaded into empty telescoping
gelatin capsules, such that each capsule contains an
amount of a ~uinoxaline effective to suppress the
*Trademark
~533~
X-4398A -37-
growth of influenza virus, either prospective or
present. In other words, the compounds can be used
prophylactically or as curative agents. Alterna-
tively, the drug can be mixed with various excipients
including starch, lubricating agents, wetting agents,
etc., such as stearic acid, magnesium stearate and the
like, and the mixture pressed into tablets, each
tablet containing an amount of the drug effective to
abort or cure an attack of influenza~ Such tablets
can be scored so as to provide half or quarter dosages
where the drug is to be administered to children. The
compounds can also be a~ministered in solution or
suspension.
Compounds represented by one or more of
formulae I, II, III and X above are administered to
mammals susceptible to infec~ion wi~h influenza virus
including horses, mice, pigs and humans. Among
humans, the compounds are administered prophylactically
particularly to the elderly, young children, nurses,
doctors, and other hospital or public health personnel,
when there is evidence of an imminent "flu" epidemic.
The compounds can also be given to anyone having a
known exposure to a person with "flu". It is a
particular advantage of the therapeutic processes of
this invention that the compounds may be administered
either prophylactically or therapeutically to patients
without a preliminary determination that the virus i9
influenza virus A strain or B strain, since the
compounds are effective against both strains.
;,~
